American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
BL
BlackRock Technology & Private Equity Term Trust
$8.74
-0.23%
NYSE: BTX · 15-min delayed
$1.0BMarket cap
BTXNYSE
2021IPO
About BlackRock Technology & Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Market cap
- $1.0B
Multi-year
Revenue & profit trend
FY2014
FY2015
FY2016
FY2017
FY2021
Revenue Net income
FY 2021
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $113.6M
- Operating income
- -$113.6M
- Income tax
- $5.0K
- Net income
- -$122.3M
- EPS (basic)
- $-2.82
- EPS (diluted)
- $-2.82
Balance sheet
- Total assets
- $32.4M
- Current assets
- $18.8M
- Total liabilities
- $25.9M
- Current liabilities
- $3.7M
- Shareholders’ equity
- $6.5M
Cash flow
- Operating cash flow
- -$23.5M
- Investing cash flow
- -$22.7M
- Financing cash flow
- $61.6M
- Net cash flow
- $15.4M
Statements via Polygon.io (SEC filings)
- Market cap
- $1.0B
- EPS (diluted)
- $-2.82
- Dividend yield
- 7.21%
- Shares outstanding
- 117.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 26, 2021
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Trading 6% below its 52-week high.
- Pays a dividend yielding about 7.21% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BlackRock Technology & Private Equity Term Trust.
Write a review
Newsroom
News about BlackRock Technology & Private Equity Term Trust
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Brooklyn ImmunoTherapeutics Announces Board Changes
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
News & sentiment via Polygon.io
Explore
Browse all →
